The once diminishing hormone replacement therapy (HRT) for menopausal symptoms market is forecast to grow from $1.6 billion in 2007 to $2.8 billion in 2017, reflecting a growth in volume sales from 1.9 billion to two billion. Short-term strategies that tried to facilitate recovery from the damning findings of the Women's Heath Initiative (WHI) study, which linked HRT to cancer and cardiovascular safety risks, will give way to more dynamic changes; development of innovative treatment options and a growing number of women who want pharmaceutical intervention for their menopausal symptoms will maintain market growth.
Source: Datamonitor, Commercial and Pipeline Insight: HRT for Menopausal Symptoms - A new class restores an old market
